



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office  
production.office@frontiersin.org

SPECIALTY SECTION  
This article was submitted to  
Sport and Exercise Nutrition,  
a section of the journal  
Frontiers in Nutrition

RECEIVED 26 August 2022  
ACCEPTED 26 August 2022  
PUBLISHED 27 September 2022

CITATION  
Frontiers Production Office (2022)  
Erratum: Effects of quercetin glycoside  
supplementation combined with  
low-intensity resistance training on  
muscle quantity and stiffness: A  
randomized, controlled trial.  
*Front. Nutr.* 9:1028810.  
doi: 10.3389/fnut.2022.1028810

COPYRIGHT  
© 2022 Frontiers Production Office.  
This is an open-access article  
distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](#). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Erratum: Effects of quercetin glycoside supplementation combined with low-intensity resistance training on muscle quantity and stiffness: A randomized, controlled trial

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

muscle quality, shear wave elastography, passive muscle stiffness, whole-body lean mass, nutrition and exercise

## An Erratum on

[Effects of quercetin glycoside supplementation combined with low-intensity resistance training on muscle quantity and stiffness: A randomized, controlled trial](#)

by Otsuka, Y., Miyamoto, N., Nagai, A., Izumo, T., Nakai, M., Fukuda, M., Arimitsu, T., Yamada, Y., and Hashimoto, T. (2022). *Front. Nutr.* 9:912217. doi: 10.3389/fnut.2022.912217

Due to a production error, there was a mistake in [Table 2](#) as published. In [Table 2](#), the asterisk mark (\*), indicating  $*p < 0.05$  compared with the placebo group (Dunnett's test), is incorrectly shown in the row "SWV with the knee fully flexed," subcategory "Placebo," and column "Change ( $\Delta$  24 weeks)." The corrected [Table 2](#) appears below.

The publisher apologizes for this mistake. The original article has been updated.

TABLE 2 Effects of the intervention on muscle quantity and stiffness in the PPS analysis.

Variable	Group	Baseline	12 weeks	24 weeks	Change ( $\Delta$ 12 weeks)	Change ( $\Delta$ 24 weeks)	Two-way ANOVA (group $\times$ time) <i>P</i> -value
MRI measurements							
Thigh muscle CSA (cm <sup>2</sup> )	Placebo	98.7 $\pm$ 17.4	102.0 $\pm$ 18.5	104.2 $\pm$ 19.2	3.3 $\pm$ 2.6	5.5 $\pm$ 3.6	0.915
	Low-QG	102.7 $\pm$ 25.4	106.2 $\pm$ 25.8	109.0 $\pm$ 28.2	3.4 $\pm$ 2.4	6.3 $\pm$ 4.4	
	High-QG	101.0 $\pm$ 25.3	105.1 $\pm$ 26.9	107.3 $\pm$ 27.4	4.1 $\pm$ 2.6	6.3 $\pm$ 4.5	
VL muscle CSA (cm <sup>2</sup> )	Placebo	17.0 $\pm$ 3.6	17.6 $\pm$ 3.8	17.8 $\pm$ 3.9	0.6 $\pm$ 0.7	0.9 $\pm$ 0.9	0.635
	Low-QG	18.3 $\pm$ 4.1	18.9 $\pm$ 4.2	19.5 $\pm$ 5.0	0.6 $\pm$ 0.8	1.2 $\pm$ 1.3	
	High-QG	17.7 $\pm$ 4.6	18.1 $\pm$ 4.6	18.5 $\pm$ 4.9	0.5 $\pm$ 0.7	0.8 $\pm$ 0.9	
DXA measurements							
Leg lean mass (kg)	Placebo	13.2 $\pm$ 2.3	13.5 $\pm$ 2.5	13.6 $\pm$ 2.7	0.3 $\pm$ 0.4	0.3 $\pm$ 0.6	0.332
	Low-QG	13.7 $\pm$ 3.8	14.1 $\pm$ 3.9	13.9 $\pm$ 3.9	0.5 $\pm$ 0.4	0.2 $\pm$ 0.4	
	High-QG	13.1 $\pm$ 3.4	13.3 $\pm$ 3.6	13.4 $\pm$ 3.5	0.2 $\pm$ 0.5	0.3 $\pm$ 0.3	
Arm lean mass (kg)	Placebo	4.1 $\pm$ 1.1	4.2 $\pm$ 1.1	4.2 $\pm$ 1.1	0.1 $\pm$ 0.1	0.0 $\pm$ 0.1	0.489
	Low-QG	4.2 $\pm$ 1.4	4.2 $\pm$ 1.4	4.2 $\pm$ 1.4	0.0 $\pm$ 0.1	0.0 $\pm$ 0.2	
	High-QG	4.1 $\pm$ 1.3	4.1 $\pm$ 1.3	4.1 $\pm$ 1.2	0.1 $\pm$ 0.2	0.0 $\pm$ 0.1	
Whole-body lean mass (kg)	Placebo	40.0 $\pm$ 6.9	40.7 $\pm$ 6.9	40.8 $\pm$ 7.3	0.6 $\pm$ 0.6	0.8 $\pm$ 0.9	0.904
	Low-QG	40.6 $\pm$ 9.9	41.4 $\pm$ 10.1	41.4 $\pm$ 10.3	0.7 $\pm$ 0.7	0.8 $\pm$ 1.0	
	High-QG	39.8 $\pm$ 9.4	40.3 $\pm$ 9.4	40.6 $\pm$ 9.1	0.5 $\pm$ 0.6	0.8 $\pm$ 1.0	
SWE measurements of VL							
SWV with the knee fully extended (m/s)	Placebo	2.0 $\pm$ 0.1	2.0 $\pm$ 0.1	2.0 $\pm$ 0.1	0.0 $\pm$ 0.1	0.0 $\pm$ 0.1	0.452
	Low-QG	1.9 $\pm$ 0.1	1.9 $\pm$ 0.2	1.9 $\pm$ 0.1	0.0 $\pm$ 0.2	0.0 $\pm$ 0.1	
	High-QG	2.0 $\pm$ 0.1	1.9 $\pm$ 0.2	2.0 $\pm$ 0.1	0.0 $\pm$ 0.1	0.0 $\pm$ 0.1	
SWV with the knee flexed at 90° (m/s)	Placebo	3.0 $\pm$ 0.2	2.9 $\pm$ 0.2	2.8 $\pm$ 0.2	-0.1 $\pm$ 0.2	-0.2 $\pm$ 0.2	0.811
	Low-QG	2.9 $\pm$ 0.2	2.8 $\pm$ 0.3	2.7 $\pm$ 0.1	-0.1 $\pm$ 0.2	-0.1 $\pm$ 0.2	
	High-QG	2.9 $\pm$ 0.3	2.8 $\pm$ 0.3	2.8 $\pm$ 0.2	-0.2 $\pm$ 0.2	-0.2 $\pm$ 0.2	
SWV with the knee fully flexed (m/s)	Placebo	4.7 $\pm$ 0.6	4.6 $\pm$ 0.5	4.4 $\pm$ 0.4 <sup>§§</sup>	-0.1 $\pm$ 0.3	-0.3 $\pm$ 0.4	0.023
	Low-QG	5.0 $\pm$ 0.5	4.7 $\pm$ 0.6 <sup>§§</sup>	4.4 $\pm$ 0.4 <sup>§§</sup>	-0.4 $\pm$ 0.3	-0.6 $\pm$ 0.3*	
	High-QG	5.0 $\pm$ 0.8	4.8 $\pm$ 0.8	4.4 $\pm$ 0.5 <sup>§§</sup>	-0.2 $\pm$ 0.5	-0.6 $\pm$ 0.5*	

Values are expressed as means  $\pm$  standard deviation. For the placebo (n = 16), low-QG (n = 16), and high-QG (n = 16) groups on MRI, DXA, and SWE measurements, where one set of SWE measurements in the placebo group at 12 weeks was missing because of no visit, there were no significant differences among the groups at baseline (one-way ANOVA). \*p < 0.05 compared with placebo group (Dunnett's test). §§p < 0.01 compared with values at baseline (Dunnett's test). QG, quercetin glycoside; MRI, magnetic resonance imaging; CSA, cross-sectional area; VL, vastus lateralis; DXA, dual energy X-ray absorptiometry; SWE, shear wave elastography; and SWV, shear wave velocity.